Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: A prospective, case-control study of predictors and resolution in HIV-infected patients

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Gupta, Samir K ^a   Anderson, Albert M ^b   Ebrahimi, Ramin ^c   Fralich, Todd ^c   Graham, Hiba ^c   Scharen Guivel, Valeska ^c   Flaherty, John F ^c   Fortin, Claude ^d   Kalayjian, Robert C ^e   Rachlis, Anita ^f   Wyatt, Christina M ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e METROHEALTH MEDICAL CENTER   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PHASE 4 CLINICAL TRIAL; PREDICTION; PROSPECTIVE STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CREATININE; FANCONI SYNDROME; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84908539950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092717     Document Type: Article

References (30)

1. (2012) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services
2. Hammer SM, Eron JJ Jr., Reiss P, Schooley RT, Thompson MA, et al (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
3. Gupta SK (2008) Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. Aids Patient Care STDS 22: 99-103.
4. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505.
5. O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, et al. (2011) Low incidence of renal impairment observed in tenofovir-treated patients. J Antimicrob Chemother 66: 1120-1126.
6. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy. J Infect Dis 197: 102-108. (Pubitemid 351263473)
7. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, et al. (2006) Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. J Infect Dis 194: 1481-1491. (Pubitemid 44851889)
8. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, et al. (2011) Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 204: 145-153.
9. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, et al. (2011) Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients. PLoS ONE 6: e22661.
10. Gerard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, et al. (2007) Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther 12: 31-39. (Pubitemid 46340423)
11. Wever K, van Agtmael MA, Carr A (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81.
12. Yoshino M, Yagura H, Kushida H, Yonemoto H, Bando H, et al. (2011) Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation. J Infect Chemother.
13. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, et al. (2004) Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study. J Acquir Immune Defic Syndr 37: 1489-1495. (Pubitemid 39602339)
14. Gallant JE, Parish MA, Keruly JC, Moore RD (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40: 1194-1198. (Pubitemid 40490248)
15. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, et al. (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23: 689-696.
16. Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, et al. (2011) Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 80: 302-309.
17. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
18. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, et al (2002) Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 1257-1263. (Pubitemid 34666660)
19. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C (2005) Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. Aids Patient Care STDS 19: 421-424. (Pubitemid 41105521)
20. Brennan A, Evans D, Maskew M, Naicker S, Ive P, et al. (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 1603-1609.
21. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, et al. (2012) Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration. J Acquir Immune Defic Syndr.
22. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, et al. (2008) The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83: 265-272.
23. Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni MC, et al. (2013) Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function. Antimicrob Agents Chemother 57: 1840-1843.
24. Atta MG, Lucas GM, Fine DM (2008) HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther 6: 365-371.
25. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, et al. (2007) Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18: 2968-2974. (Pubitemid 350058405)
26. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, et al. (2007) The impact of HIV on chronic kidney disease outcomes. Kidney Int 72: 1380-1387. (Pubitemid 350126779)
27. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. (2006) Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-infected Patients. J Acquir Immune Defic Syndr.
28. Bonjoch A, Echeverria P, Perez-Alvarez N, Puig J, Estany C, et al. (2012) High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res 96: 65-69.
29. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, et al. (2013) Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya. J Infect Dis.
30. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, et al. (2009) The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 14: 543-549.